12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Humira adalimumab: Additional Phase III data

Additional data from the double-blind, international Phase III ABILITY-1 trial in 179 patients with active non-radiographic axial spondyloarthritis showed that Humira significantly improved Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) scores at week 12 vs. placebo (reductions of 0.3 vs. 0.1 points, p=0.025). Humira also significantly improved SF-36 physical component summary scores at week 12 vs. placebo (5.5 vs. 2 points, p<0.001).

A post hoc analysis of the open-label extension study of the ABILITY-1 trial showed that 62% patients receiving Humira met the minimum important difference...

Read the full 409 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >